Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Innovent Biologics Announces First Patient Dosed in the Pivotal Registrational Trial of Pemigatinib in Patients with Advanced Cholangiocarcinoma in China

prnasiaMarch 04, 2020

Tag: Innovent Biologics , Pivotal Registrational Trial , cholangiocarcinoma

PharmaSources Customer Service